Exagen Q1 Revenue Surpasses Estimates by 5.5%, Reaching $17.3 Million
summarizeSummary
Exagen Inc. announced first-quarter revenue of $17.306 million, exceeding the IBES consensus estimate of $16.4 million by approximately 5.5%. This top-line beat is a positive development for the company, which reported full-year 2025 revenue of $66.6 million. Despite the revenue outperformance, Exagen recorded a net loss of $3.967 million for the quarter. For a company of Exagen's size, beating revenue estimates can be a significant catalyst, potentially signaling improving demand for its diagnostic products. Traders will be watching for continued revenue growth and the company's path to profitability in upcoming reports.
At the time of this announcement, XGN was trading at $3.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $71M. The 52-week trading range was $2.59 to $12.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.